In Argentina, Ampligen has just been commercially approved for severe ME/CFS

PHILADELPHIA, Aug. 23, 2016 (GLOBE NEWSWIRE)

  "“In Argentina, rintatolimod (Ampligen) has just been commercially approved for the severe disabling form of ME/CFS.  The number of patients with ME/CFS is estimated to be over three million worldwide, however, only a portion of these have the severe and disabling form of the disease which we are targeting with this drug,” stated Tom Equels."

  "Several post-approval activities are required to be completed before product launch, including manufacturing site inspections and reimbursement evaluation by the Health Services Authority (SSS), the central health authority in Argentina."